Latest Industry Insights

In this interview, Rolland Carlson, PhD, CEO of Immunexpress, discusses sepsis and the company’s FDA cleared SeptiCyte® RAPID test, as well as a take on the company’s differentiated value and outlook.

In this interview, Gregory J. McKenzie, PhD, discusses the impact of antibiotics, the introduction of new bacteria into the microbiome and the potential of human breast milk-based therapeutics.

The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.

Technology Networks learns about the "unusual" spread of the monkeypox virus in non-endemic countries, possible vaccination strategies against the virus and if there are effective treatments available.

Technology Networks learns about serum epitope repertoire analysis and some of the applications it could benefit, including cancer diagnostics and COVID-19 studies.

At the recent Bio-IT World 2022 conference, Andrew LeBeau, associate vice president of product integrations at Dotmatics, gave a talk on the benefits that automation can bring to antibody discovery workflows. We spoke with LeBeau to find out more about these benefits and how Dotmatics’ approach meets one of the key themes of the conference, FAIR data principles.

Technology Networks spoke to Francisco Bizouarn, market development manager of the Digital Biology Group at Bio-Rad Laboratories, to find out how wastewater testing works and how it can anticipate a rise in cases of COVID-19 and the emergence of new variants.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

Technology Networks had the pleasure of speaking to Thomas Lendvay, CMO and co-founder of Tend about the current applications of gut microbiota transplants and how they could be used in future.

While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.